Sponsor Directory

Genentech, Inc. clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 11:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1397

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Polypoidal Choroidal Vasculopathy
Interventions: ranibizumab 0.5 or 2.0 mg/0.05 cc; Drug
Lead sponsor: Southeast Retina Center, Georgia; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Breast Neoplasms, Malignant Tumor of the Breast
Interventions: Trastuzumab, Pertuzumab, Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine; Drug
Lead sponsor: US Oncology Research; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Multiple Locations, Texas

Conditions: Esophageal Cancer, Gastric Cancer, Stomach Cancer
Interventions: Bevacizumab, Cisplatin, Irinotecan, Docetaxel; Drug · Device
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 4
States / cities: Boston, Massachusetts • Nashville, Tennessee • Dallas, Texas

Conditions: Liver Cancer
Interventions: Bevacizumab, Erlotinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Neoplasms
Interventions: Doxorubicin, Trastuzumab, Cyclophosphamide, Paclitaxel, Epirubicin, Docetaxel, Carboplatin, Fluorouracil; Drug · Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetic Macular Edema
Interventions: Lucentis; Drug
Lead sponsor: Vitreo-Retinal Associates, Michigan; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Breast Cancer
Interventions: Crofelemer; Drug
Lead sponsor: Sandra Swain; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Hackensack, New Jersey

Conditions: Breast Cancer, Cancer of the Breast, Breast Neoplasm
Interventions: Letrozole (Femara), Letrozole; Avastin; Other · Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2022
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 4 more

Conditions: Acute Myelogenous Leukemia, AML
Interventions: Venetoclax, Cytarabine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 60 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 5
States / cities: Kansas City, Kansas • New York, New York • Pittsburgh, Pennsylvania + 2 more

Conditions: Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
Interventions: Venetoclax, Rituximab, Etoposide, Vincristine Sulfate, Cyclophosphamide, Prednisone, Doxorubicin Hydrochloride; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 6
States / cities: Boston, Massachusetts • St Louis, Missouri • New York, New York + 3 more

Conditions: Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions: Biomarker Analysis, Enzalutamide, Pharmacological Study, Taselisib; Other · Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 12
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 9 more

Conditions: Disorder Related to Lung Transplantation, Chronic Lung Allograft Dysfunction
Interventions: Pirfenidone Capsule, Placebo Capsule; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

About this Genentech, Inc. sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where Genentech, Inc. is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Genentech, Inc. trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Genentech, Inc. clinical trials

Filter and sort this sponsor

Live official records

Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy

Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer

Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer

Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy

Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis

Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients

Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer

A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia

Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)

About this Genentech, Inc. sponsor directory page